Klotz et al. (abstract no. 1682) presented data on Tuesday updating information about their 14-year-long series of patients managed with active surveillance.
Filed under: Management, Treatment | Tagged: active surveillance | 6 Comments »
AUA report and update no. 10: Thursday, April 30, 2009
Posted on April 30, 2009 by Sitemaster
In a plenary session on Tuesday, Dr. William Aronson summarized current understanding about the impact of diet and lifestyle on prostate cancer development and progression.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Prevention | Tagged: antibiootic therapy, diet, exercise, potency | Leave a Comment »
Over 380,000 new cases a year in 2030?
Posted on April 30, 2009 by Sitemaster
A paper just published in the Journal of Clinical Oncology ( and available in full on line) includes data projecting 382,000 new cases of prostate cancer in the USA in 2030.
Filed under: Diagnosis, Prevention, Risk | Tagged: epidemiology, incidence | 1 Comment »
Gen-Probe to initiate Phase III trial of PCA3 test in USA
Posted on April 29, 2009 by Sitemaster
The prostate cancer gene 3 or PCA3 test has been available for some time under research protocols in the USA. This means that while the test has been accessible at a cost, it has not been available as a standard commercial test (in the same way as a PSA test is). Today, however, Gen-Probe has [...]
Filed under: Diagnosis, Risk | 5 Comments »
New Phase III trial of abiraterone in CRPC starts TODAY!
Posted on April 29, 2009 by Sitemaster
According to a media release from Cougar Biotechnology, a second Phase III clinical trial of abiraterone acetate started today — for men with castration-resistant prostate cancer (CRPC) who have not received chemotherapy.
Filed under: Drugs in development | Tagged: abiraterone acetate, CRPC, Phase III | 10 Comments »
AUA report and update no. 9: Wednesday, April 29, 2009
Posted on April 29, 2009 by Sitemaster
Two papers presented at the meeting on Monday this week addressed radical prostatectomy in high risk patients and different applications of androgen deprivation therapy for their impact on overall patient survival, using the Johns Hopkins patient database as their starting point.
Filed under: Management, Treatment | Tagged: "high risk", ADT, androgen deprivation therapy, radical prostatectomy, survial | Leave a Comment »
New AUA “best practice statement” on use of PSA
Posted on April 29, 2009 by Sitemaster
The American Urological Association’s complete new statement on the use of PSA is now available on the AUA web site. New consumer- and patient-directed information about PSA testing is now available on the web site of the AUA Foundation.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment, Uncategorized | Tagged: best practice, guidelines, PSA | 2 Comments »
AUA report and update no. 8: Wednesday, April 29, 2009
Posted on April 29, 2009 by Sitemaster
Two studies presented at the AUA on Monday dealt with the mortality rates of men diagnosed with prostate cancer and treated with differing types of first line therapy.
Filed under: Management, Treatment, Uncategorized | Tagged: mortality, overall, prostate cancer-specific | Leave a Comment »
The IMPACT trial results: Tuesday April 27, 2009
Posted on April 28, 2009 by Sitemaster
OK … so here are the results we have all been waiting for for the past few weeks — the data from the IMPACT trial comparing the survival of patients treated with three doses of sipuleucel-T (Provenge) to placebo in men with androgen-independent prostate cancer.
Filed under: Drugs in development | Tagged: androgen-independent prostate cancer, Dendreon, Provenge, sipuleucel-T | 2 Comments »
AUA report and update no. 6: Monday, April 27, 2009
Posted on April 27, 2009 by Sitemaster
We learned a few other interesting tidbits during a variety of sessions and conversations today.
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Prevention, Risk, Treatment, Uncategorized | Tagged: abiraterone, bevacizumab, density, early, hormone therapy, late, risk, statin, urologist | Leave a Comment »
AUA report and update no. 5: Monday, April 27, 2009
Posted on April 27, 2009 by Sitemaster
So Dr Gerry Andriole just completed his presentation of the main results of the REDUCE trial, designed to test the ability of dutasteride (Avodart) to prevent prostate cancer in men believed to be at high risk for this disease — and the results are positive.
Filed under: Diagnosis, Prevention, Risk | Tagged: dutasteride, Prevention, REDUCE | Leave a Comment »
AUA report and update no. 4: Monday, April 27, 2009
Posted on April 27, 2009 by Sitemaster
The American Urological Association (AUA) has issued new guidance on the use of PSA testing in the early detection of prostate cancer.
Filed under: Diagnosis, Risk | Tagged: guidelines, PSA, screening | 1 Comment »
AUA report and update no. 3: Sunday, April 26, 2009
Posted on April 26, 2009 by Sitemaster
The following four reports address some other interesting papers and posters presented at the AUA today.
Filed under: Management, Treatment | Tagged: active surveillance, dosing, Epsetins's criteria, Gleason score, LHRH therapy, positive surgical margins | Leave a Comment »
AUA report and update no. 2: Sunday, April 26, 2009
Posted on April 26, 2009 by Sitemaster
Two important papers presented this afternoon addressed data on the use of toremifene and denosumab on the bones of men receiving treatment with androgen deprivation therapy (ADT).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation therapy, bone mineral denisty, denosumab, fractures, toremifene | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
